Cardiotoxicity in Childhood Cancer Survivors: Strategies for Prevention and Management

• Mariotto AB , RowlandJH, YabroffKRet al. Long-term survivors of childhood cancers in the United States. Cancer Epidemiol. Biomarkers Prev. , 18, 1033–1040 (2009).
   PubMed Web of Science ®Google Scholar
• Hinkle AS , ProukouC, FrenchCAet al. A clinic-based, comprehensive care model for studying late effects in long-term survivors of pediatric illnesses. Pediatrics , 113(Suppl. 4), 1141–1145 (2004).
   PubMed Web of Science ®Google Scholar
• Reulen RC , WinterDL, FrobisherCet al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA , 304(2), 172–179 (2010).
   PubMed Web of Science ®Google Scholar
• Mulrooney DA , YeazelMW, KawashimaTet al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor study cohort. BMJ , 339, b4606 (2009).
   PubMed Web of Science ®Google Scholar
• van der Pal HJ et al. , van Dalen EC, van Delden E High risk of symptomatic cardiac events in childhood cancer survivors. J. Clin. Oncol., 30(13), 1429–1437 (2012).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , AdamsMJ. Cardiotoxicity after childhood cancer: beginning with the end in mind. J. Clin. Oncol., 28(8), 1276–1281 (2010).
   PubMed Web of Science ®Google Scholar
• Hudson MM , MertensAC, YasuiYet al. Health status of adult long-term survivors of childhood cancer: a report from the childhood cancer survivor study. JAMA , 290(12), 1583–1592 (2003).
   PubMed Web of Science ®Google Scholar
• Mody R , LiS, DoverDCet al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor study. Blood , 111(12), 5515–5523 (2008).
   PubMed Web of Science ®Google Scholar
• Miller TL , LipsitzSR, Lopez-MitnikGet al. Characteristics and determinants of adiposity in pediatric cancer survivors. Cancer Epidemiol. Biomarkers Prev. , 19(8), 2013–2022 (2010).
   PubMed Web of Science ®Google Scholar
• National Research Council. Chapter 4: late effects of childhood cancer. In: Childhood Cancer Survivorship: Improving Care and Quality of Life. Hewitt M, Weiner SL, Simone JV (Eds). National Academic Press, DC, USA, 48–49 (2003).
   Google Scholar
• Alvarez JA , ScullyRE, MillerTLet al. Long-term effects of treatments for childhood cancers. Curr. Opin. Pediatr. , 19, 23–31 (2007).
   PubMed Web of Science ®Google Scholar
• van Dalen EC , RaphaëlMF, CaronHN, KremerLC. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. Cochrane Database Syst. Rev., 1, CD006647 (2009).
   Google Scholar
• Fulbright JM , HuhW, AndersonP, ChandraJ. Can anthracycline therapy for pediatric malignancies be less cardiotoxic? Curr. Oncol. Rep., 12(6), 411–419 (2010).
   PubMed Web of Science ®Google Scholar
• Herman EH , FerransVJ, JordanW, ArdalanB. Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. Res. Commun. Chem. Pathol. Pharmacol., 31(1), 85–97 (1981).
   PubMedGoogle Scholar
• Herman EH , el-HageAN, FerransVJ, ArdalanB. Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats. Toxicol. Appl. Pharmacol., 78(2), 202–214 (1985).
   PubMed Web of Science ®Google Scholar
• Outomuro D , GranaDR, AzzatoF, MileiJ. Adriamycin-induced myocardial toxicity: new solutions for an old problem? Int. J. Cardiol., 117(1), 6–15 (2007).
   PubMed Web of Science ®Google Scholar
• Mordente A , MeucciE, MartoranaGE, GiardinaB, MinottiG. Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life, 52, 83–88 (2001).
   PubMed Web of Science ®Google Scholar
• Wouters KA , KremerLC, MillerTL, HermanEH, LipshultzSE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br. J. Haematol., 131(5), 561–578 (2005).
   PubMed Web of Science ®Google Scholar
• Gianni L , ZweierJL, LevyA, MyersCE. Characterization of the cycle of iron-mediated electron transfer from adriamycin to molecular oxygen. J. Biol. Chem., 260(11), 6820–6826 (1985).
   PubMed Web of Science ®Google Scholar
• Olson RD , MushlinPS. Doxorubicin cardiotoxicity: analysis of prevailing hypothesis. FASEB J., 4(13), 3076–3086 (1990).
   PubMed Web of Science ®Google Scholar
• Milei J , BoverisA, LlesuySet al. Amelioration of adriamycin-induced cardiotoxicity in rabbits by prenylamine and vitamins A and E. Am. Heart J. , 111, 95–102 (1986).
   PubMed Web of Science ®Google Scholar
• Ferrero ME , FerreroE, GajaU. Adriamycin: energy metabolism and mitochondrial oxidations in the heart of treated rabbits. Biochem. Pharmacol., 25(2), 125–130 (1976).
   PubMed Web of Science ®Google Scholar
• Earm YE , HoWK, SoI. Effects of adriamycin on ionic currents in single cardiac myocytes of the rabbit. J. Mol. Cell. Cardiol., 26(2), 163–172 (1994).
   PubMed Web of Science ®Google Scholar
• Olson RD , LiX, PaladePet al. Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol. Toxicol. Appl. Pharmacol. , 169(2), 168–176 (2000).
   PubMed Web of Science ®Google Scholar
• Gozalvez M , BlancoM. Inhibition of NA-K ATPase by the antitumor antibiotic adriamycin. 5th International Biophysics Congress, Copenhagen. Cancer Res., 39(1), 257–261 (1979).
   PubMed Web of Science ®Google Scholar
• Lou H , DanelisenI, SingalPK. Cytokines are not upregulated in adriamycin-induced cardiomyopathy and heart failure. J. Mol. Cell. Cardiol., 36(5), 683–690 (2004).
   PubMed Web of Science ®Google Scholar
• Lenaz L , PageJA. Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat. Rev., 3(3), 111–120 (1976).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , RusconiP, ScullyRE. Chapter 18: assessment of cardiotoxicity during anti-cancer therapy. In: NT-proBNP as a Biomarker in Cardiovascular Diseases. Januzzi JL, Bayes-Genis A (Eds). Prous Science SA, Barcelona, Spain, 193–198 (2007).
   Google Scholar
• Pointon AV , WalkerTM, PhillipsKMet al. Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation. PLoS ONE , 5(9), e12733 (2010).
   PubMed Web of Science ®Google Scholar
• Gonzalvez F , GottliebE. Cardiolipin: setting the beat of apoptosis. Apoptosis, 12(5), 877–885 (2007).
   PubMed Web of Science ®Google Scholar
• Goormaghtigh E , BrasseurR, HuartP, RuysschaertJM. Study of the adriamycin cardiolipin complex structure using attenuated total reflection infrared spectroscopy. Biochemistry, 26(6), 1789–1794 (1987).
   PubMed Web of Science ®Google Scholar
• Garcia Fernandez M , TroianoL, MorettiL. Early changes in intramitochondrial cardiolipin distribution during apoptosis. Cell Growth Differ., 13(9), 449–455 (2002).
   PubMedGoogle Scholar
• Aguilar L , Ortega-PierresG, CamposBet al. Phospholipid membranes form specific nonbilayer molecular arrangements that are antigenic. J. Biol. Chem. , 274(36), 25193–25196 (1999).
   PubMed Web of Science ®Google Scholar
• Vlasova II , TyurinVA, KapralovAAet al. Nitric oxide inhibits peroxidase activity of cytochrome C cardiolipin complex and blocks cardioliopin oxidation. J. Biol. Chem. , 281(21), 14554–14562 (2006).
   PubMed Web of Science ®Google Scholar
• Arola OJ , SarasteA, PulkkiK, KallajokiM, ParvinenM, Voipio-PulkkiLM. Acute doxorubicin cardiotoxicity involves cardiomyocte apoptosis. Cancer Res., 60(7), 1789–1792 (2000).
   PubMed Web of Science ®Google Scholar
• Zhang YQ , ShiJ, LiYJ, WeiL. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch. Immunol. Ther. Exp., 57(6), 435–445 (2009).
   PubMed Web of Science ®Google Scholar
• Adams MJ , LipshultzSE. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr. Blood Cancer, 44(7), 600–606 (2005).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , ColanSD, GelberRD, Perez-AtaydeAR, SallanSE, SandersSP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med., 324(12), 808–815 (1991).
   PubMed Web of Science ®Google Scholar
• Sorensen K , LevittG, BullC, ChessellsJ, SullivanI. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. J. Clin. Oncol., 15(1), 61–68 (1997).
   PubMed Web of Science ®Google Scholar
• Giantris A , AbdurrahmanL, HinkleAet al. Anthracycline-induced cardiotoxicity in children and young adults. Crit. Rev. Oncol. Hematol. , 27, 53–68 (1998).
   PubMed Web of Science ®Google Scholar
• Doroshow JH , LockerGY, MyersCE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J. Clin. Invest., 65(1), 128–135 (1980).
   PubMed Web of Science ®Google Scholar
• Cascales A , Sanchez-VegaB, NavarroN, Pastor-QuiranteF, CorralJ, VicenteV, de la Pena FA. Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation. Int. J. Cardiol., 154(3), 282–286 (2010).
   PubMed Web of Science ®Google Scholar
• Arai M , YoguchiA, TakizawaTet al. Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca2+-ATPase gene transcription. Circ. Res. , 86(1), 8–14 (2000).
   PubMed Web of Science ®Google Scholar
• Jeyaseelan R , PoizatC, WuHY, KedesL. Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. J. Biol. Chem., 272(9), 5828–5832 (1997).
   PubMed Web of Science ®Google Scholar
• Lebrecht DMS , SetzerB, KetelsenUP, HaberstrohJ, WalkerUA. Time-dependant and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation, 108(19), 2423–2429 (2003).
   PubMed Web of Science ®Google Scholar
• Arola OJ , SarasteA, PulkkiK, KallajokiM, ParvinenM, Voipio-PulkkiLM. Acute doxorubicin cardiotoxicity involves cardiomyocte apoptosis. Cancer Res., 60(7), 1789–1792 (2000).
   PubMed Web of Science ®Google Scholar
• Childs AC , PhaneufSL, DirksAJ, PhillipsT, LeeuwenburghC. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res., 62(16), 4592–4598 (2002).
   PubMed Web of Science ®Google Scholar
• Von Hoff DD , LayardM, BasaPet al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. , 91(5), 710–717 (1979).
   PubMed Web of Science ®Google Scholar
• Swain SM , WhaleyFS, EwerMS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer, 97(11), 2869–2879 (2003).
   PubMed Web of Science ®Google Scholar
• van Dalen EC , van der Pal HJ, Kok WE, Caron HN, Kremer LC. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur. J. Cancer, 42(18), 3191–3198 (2006).
   PubMed Web of Science ®Google Scholar
• van der Pal HJ et al. , van Dalen EC, Hauptmann M Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch. Intern. Med., 170(14), 1247–1255 (2010).
   PubMedGoogle Scholar
• Blanco JG , SunCL, LandierWet al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes – a report from the Children‘s Oncology Group. J. Clin. Oncol. , 30(13), 1415–1421 (2012).
   PubMed Web of Science ®Google Scholar
• van Dalen EC , CaronHN, DickinsonHO, KremerLCM. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst. Rev., 25(1), CD003917. Update in: Cochrane Database Syst. Rev., 2011(6), CD003917 (2005).
   Google Scholar
• Lipshultz SE , LipsitzSR, SallenSEet al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J. Clin. Oncol. , 23(12), 2629–2636 (2005).
   PubMed Web of Science ®Google Scholar
• Davies SM . Getting to the heart of the matter. J. Clin. Oncol., 30(13), 1399–1400 (2012).
   PubMed Web of Science ®Google Scholar
• Visscher H , RossCJD, RassekhSRet al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J. Clin. Oncol. , 30(13), 1422–1428 (2012).
   PubMed Web of Science ®Google Scholar
• Krischer JP , EpsteinS, CuthbertsonDD, GoorinAM, EpsteinML, LipshultzSE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J. Clin. Oncol., 15, 1544–1552 (1997).
   PubMed Web of Science ®Google Scholar
• Sorensen K , LevittGA, BullC, DorupI, SullivanID. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer, 97(8), 1991–1998 (2003).
   PubMed Web of Science ®Google Scholar
• Nysom K , HolmK, LipsitzSRet al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J. Clin. Oncol. , 2, 545–550 (1998).
   Google Scholar
• Lipshultz SE , LipsitzSR, MoneSMet al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N. Engl. J. Med. , 332(26), 1738–1743 (1995).
   PubMed Web of Science ®Google Scholar
• Steinherz LJ , SteinherzPG, TanCT, HellerG, MurphyML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA, 266(12), 1672–1677 (1991).
   PubMed Web of Science ®Google Scholar
• Anderlini P , BengaminRS, WongFCet al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J. Clin. Oncol. , 13(11), 2827–2834 (1995).
   PubMed Web of Science ®Google Scholar
• Sorensen K , LevittG, Sebag-MontefioreD, BullC, SullivanI. Cardiac function in Wilms‘ tumor survivors. J. Clin. Oncol., 13(7), 1546–1556 (1995).
   PubMed Web of Science ®Google Scholar
• Nysom K , ColanDC, LipshultzSE. Late cardiotoxicity following anthracycline therapy for childhood cancer. Prog. Pediatr. Cardiol., 8, 121–138 (1998).
   Web of Science ®Google Scholar
• Green DM , GrigorievYA, NanBet al. Congestive heart failure after treatment for Wilms‘ tumor: a report from the National Wilms‘ Tumor Study Group. J. Clin. Oncol. , 19(7), 1926–1934 (2001).
   PubMed Web of Science ®Google Scholar
• Kremer LCM , van Dalen EC, Offringa M, Ottenkamp J, Voûte PA. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J. Clin. Oncol., 19(1), 191–196 (2001).
   PubMed Web of Science ®Google Scholar
• Tukenova M , GuiboutC, OberlinOet al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J. Clin. Oncol. , 28(8), 1308–1315 (2010).
   PubMed Web of Science ®Google Scholar
• Rodvold KA , RushingDA, TewksburyDA. Doxorubicin clearance in the obese. J. Clin. Oncol., 6(8), 1321–1327 (1998).
   Google Scholar
• Bristow MR , ThompsonPD, MartinRP, MasonJW, BillinghamME, HarrisonDC. Early anthracycline cardiotoxicity. Am. J. Med., 65(5), 823–832 (1978).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , MillerTM, ScullyREet al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J. Clin. Oncol. , 30(10), 1042–1049 (2012).
   PubMed Web of Science ®Google Scholar
• Ali MK , EwerMS, GibbsHR, SwaffordJ, GraffKL. Late doxorubicin-associated cardiotoxicity in children. The possible role of intercurrent viral infection. Cancer, 74(1), 182–188 (1994).
   PubMed Web of Science ®Google Scholar
• Tolba KA , DeliargyrisEN. Cardiotoxicity of cancer therapy. Cancer Invest., 17(6), 408–422 (1999).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , AlvarezJA, ScullyRE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart, 94(4), 525–533 (2008).
   PubMed Web of Science ®Google Scholar
• Grenier MA , LipshultzME. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin. Oncol., 25(4 Suppl. 10), 72–85 (1998).
   PubMed Web of Science ®Google Scholar
• Simbre VC , DuffySA, DadlaniGH, MillerTL, LipshultzSE. Cardiotoxicity of cancer chemotherapy: implications for children. Paediatr. Drugs, 7, 187–202 (2005).
   PubMedGoogle Scholar
• Barry E , AlvarezJA, ScullyRE, MillerTL, LipshultzSE. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin. Pharmacother., 8, 1039–1058 (2007).
   PubMed Web of Science ®Google Scholar
• Herman EH , ZhangJ, LipshultzSEet al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J. Clin. Oncol. , 17, 2237–2243 (1999).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , SandersSP, GoorinAM, KrischerJP, SallanSE, ColanSD. Monitoring for anthracycline cardiotoxicity. Pediatrics, 93, 433–437 (1994).
   PubMed Web of Science ®Google Scholar
• Carver JR , ShapiroCL, NGAet al. ASCO Cancer Survivorship Exert Panel. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J. Clin. Oncol. , 25, 3991–4008 (2007).
   PubMed Web of Science ®Google Scholar
• Steinhertz LJ , GrahamT, HurwitzRet al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the cardiology committee of the Children‘s Cancer Study Group. Pediatrics , 89, 942–949 (1992).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , SandersSP, ColanSD, GoorinAM, SallanSE, KrischerJP. Letter to the Editor. Pediatrics, 94, 781 (1994)
   Web of Science ®Google Scholar
• Adams MJ , LipshultzSE, SchwartzC, FajardoLF, CoenV, ConstineLS. Radiation-associated cardiovascular disease: manifestations and management. Semin. Radiat. Oncol., 13(3), 346–356 (2003).
   PubMed Web of Science ®Google Scholar
• Adams MJ , HardenberghPH, ConstineLS, LipshultzSE. Radiation-associated cardiovascular disease. Crit. Rev. Oncol. Hematol., 45(1), 55–75 (2003).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , RifaiN, DaltonVMet al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N. Engl. J. Med. , 351(2), 145–153 (2004).
   PubMed Web of Science ®Google Scholar
• Ganame J , ClausP, EyskensBet al. Acute cardiac functional and morphological changes after anthracycline infusions in children. Am. J. Cardiol. , 99(7), 974–977 (2007).
   PubMed Web of Science ®Google Scholar
• Ganame J , ClausP, UyttebroeckAet al. Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients. J. Am. Soc. Echocardiogr. , 20(12), 1351–1358 (2007).
   PubMed Web of Science ®Google Scholar
• Colan SD , BorrowKM, NeumanA. Left ventricular end-systolic wall stress-velocity of fiber shortening relation: a load independent index of myocardial contractility. J. Am. Coll. Cardiol., 4, 715–724 (1984).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , ColanSD. The use of echocardiography and holter monitoring in the assessment of anthracycline-treated patients. In: Cardiac Toxicity After Treatment for Childhood Cancer. Wiley-Liss, NY, USA, 45–62 (1993).
   Google Scholar
• Mitani I , JainD, JoskaTM, BurtnessB, ZaretBL. Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J. Nucl. Cardiol., 10(2), 132–139 (2003).
   PubMed Web of Science ®Google Scholar
• Glanzmann C , HugueninP, LutolfUM, MaireR, JenniR, GumppenbergV. Cardiac lesions after mediastinal radiation for Hodgkin‘s disease. Radiother. Oncol., 30(1), 43–54 (1994).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , RifaiN, SallanSEet al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation , 96(8), 2641–2648 (1997).
   PubMed Web of Science ®Google Scholar
• Levin ER , GardnerDG, SamsonWK. Natriuretic peptides. N. Engl. J. Med., 339(5), 321–328 (1998).
   PubMed Web of Science ®Google Scholar
• Cowie MR , MendezGF. BNP and congestive heart failure. Prog. Cardiovasc. Dis., 44(4), 293–321 (2002).
   PubMed Web of Science ®Google Scholar
• Linssen GC , BakkerSJ, VoorsAAet al. N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur. Heart J. , 31(1), 120–127 (2010).
   PubMed Web of Science ®Google Scholar
• Bibbins-Domingo K , GuptaR, NaBet al. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA , 297, 169–176 (2007).
   PubMed Web of Science ®Google Scholar
• Trachtenberg BH , LandyDC, FrancoVIet al. Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr. Cardiol. , 32, 342–353 (2011).
   PubMed Web of Science ®Google Scholar
• Franco VI , HenkelJM, MillerTL, LipshultzSE. Cardiovascular effects in childhood cancer survivors treated with anthracyclines. Cardiol. Res. Pract., 10, 134679 (2011).
   Google Scholar
• Schwartz CL , HobbieWL, TruesdellS, ConstineLC, ClarkEB. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J. Clin. Oncol., 11(10), 1906–1910 (1993).
   PubMed Web of Science ®Google Scholar
• Larsen RL , BarberG, HeiseCT, AugustCS. Exercise assessment of cardiac function in children and young adults before and after bone marrow transplantation. Pediatrics, 89(4 Pt 2), 722–729 (1992).
   PubMed Web of Science ®Google Scholar
• Weesner KM . Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer, 68(2), 435–438 (1991).
   PubMed Web of Science ®Google Scholar
• Adams MJ , LipsitzSR, ColanSDet al. Cardiovascular status in long-term survivors of Hodgkin‘s disease treated with chest radiotherapy. J. Clin. Oncol. , 22(15), 3139–3148 (2004).
   PubMed Web of Science ®Google Scholar
• Hogenhuis J , JaarsmaT, VoorsAA, HillegeHL, LesmanI, van Veldhuisen DJ. Correlates of B-type natriuretic peptide and 6-min walk in heart failure patients. Int. J. Cardiol., 108(1), 63–67 (2006).
   PubMed Web of Science ®Google Scholar
• Ryberg M , NielsenD, SkovsgaardT, HansenJ, JensenBV, DombernowskyP. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J. Clin. Oncol., 16(11), 3502–3508 (1998).
   PubMed Web of Science ®Google Scholar
• Legha SS , BenjaminRS, MackayBet al. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer , 49(9), 1762–1766 (1982).
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN , FryeD, BuzdarAUet al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer , 63(1), 37–45 (1989).
   PubMed Web of Science ®Google Scholar
• Shapira J , GotfriedM, LishnerM, RavidM. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regiment. A prospective evaluation. Cancer, 65(4), 870–873 (1990).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , GiantrisAL, LipsitzSRet al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91–01 Acute Lymphoblastic Leukemia protocol. J. Clin. Oncol. , 20(6), 1677–1682 (2002).
   PubMed Web of Science ®Google Scholar
• Levitt GA , DorupI, SorensenK, SullivanI. Does anthracycline administration by infusion in children affect late cardiotoxicity? Br. J. Haematol., 24(4), 463–468 (2004).
   Google Scholar
• Singal PK , IliskovicN. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med., 339(13), 900–905 (1998).
   PubMed Web of Science ®Google Scholar
• Weiss RB . The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol., 19(6), 670–686 (1992).
   PubMed Web of Science ®Google Scholar
• Ganzina F 4´-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat. Rev., 10(1), 1–22 (1983).
   PubMed Web of Science ®Google Scholar
• Lahtinen R , KuikkaJ, NousiaineneT, UusituoaM, LansimiesE. Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study. Eur. J. Haematol., 46(5), 301–305 (1991).
   PubMed Web of Science ®Google Scholar
• Cottin Y , TouzeryC, DallozFet al. Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studies by radionuclide angiography. Clin. Cardiol. , 21(9), 665–670 (1998).
   PubMed Web of Science ®Google Scholar
• Dorr RT , ShippNG, LeeKM. Comparison of cytotoxicity in heart cells and tumor cells exposed to DNA intercalating agents in vitro. Anticancer Drugs, 2(1), 27–33 (1991).
   PubMed Web of Science ®Google Scholar
• Alderton PM , GrossJ, GreenMD. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res., 52(1), 194–201 (1992).
   PubMed Web of Science ®Google Scholar
• Herman EH , ZhangJ, HasinoffBB, ClarkJRJ, FerransVJ. Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex. J. Mol. Cell. Cardiol., 29(9), 2415–2430 (1997).
   PubMed Web of Science ®Google Scholar
• Creutzig U , RitterJ, ZimmermannMet al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia , 15(3), 348–354 (2001).
   PubMed Web of Science ®Google Scholar
• Tardi PG , BomanNL, CullisPR. Liposomal doxorubicin. J. Drug Target., 4(3), 129–140 (1996).
   PubMed Web of Science ®Google Scholar
• Batist G , RamakrishnanG, RaoCSet al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. , 19(5), 1444–1454 (2001).
   PubMed Web of Science ®Google Scholar
• Harris L , BatistG, BeltRet al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multi-center trial as first-line therapy of metastatic breast carcinoma. Cancer , 94(1), 25–36 (2002).
   PubMed Web of Science ®Google Scholar
• Safra T . Cardiac safety of liposomal anthracyclines. Oncologist, 8(2), 17–24 (2003).
   PubMedGoogle Scholar
• Gabizon AA . Liposomal anthracyclines. Hematol. Oncol. Clin. North Am., 8(2), 431–450 (1994).
   PubMed Web of Science ®Google Scholar
• Money-Kyrle JF , BatesF, ReadyJ, GazzardBG, PhillipsRH, BoagFC. Liposomal daunorubicin in advanced Kaposi‘s sarcoma: a Phase II study. Clin. Oncol. (R. Coll. Radiol.), 5(6), 367–371 (1993).
   PubMedGoogle Scholar
• Gill PS , WernzJ, ScaddenDT. Randomized Phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi‘s sarcoma. J. Clin. Oncol., 14(8), 2353–2364 (1996).
   PubMed Web of Science ®Google Scholar
• O‘Brien ME , WiglerN, InbarMet al. Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. , 15(3), 440–449 (2004).
   PubMed Web of Science ®Google Scholar
• Sieswerda E , KremerLC, CaronHN, van Dalen EC: The use of liposomal anthracycline analogues for childhood malignancies: a systematic review. Eur. J. Cancer, 47(13), 2000–2008 (2011).
   PubMed Web of Science ®Google Scholar
• Zimethbaum P , EderH, FrishmanW. Probucol: pharmacology and clinical application. J. Clin. Pharmacol., 30(1), 3–9 (1990).
   PubMed Web of Science ®Google Scholar
• Carew TE , SchwenkeDC, SteinbergD. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc. Natl Acad. Sci. USA, 84(21), 7725–7729 (1987).
   PubMed Web of Science ®Google Scholar
• Kuzuya M , KuzuyaF. Probucol as an antioxidant and antiatherogenic drug. Free Radic. Biol. Med., 14(1), 67–77 (1993).
   PubMed Web of Science ®Google Scholar
• Siveski-Iliskovic N , HillM, ChowDA, SinghalPK. Probucol protects against doxorubicin cardiomyopathy without interfering with its antitumor effect. Circulation, 91(1), 10–15 (1995).
   PubMed Web of Science ®Google Scholar
• Singal PK , DeallyCM, WeinbergLE. Subcellular effects of doxorubicin in the heart. A concise review. J. Mol. Cell. Cardiol., 19(8), 817–828 (1987).
   PubMed Web of Science ®Google Scholar
• Iliskovic N , SingalPK. Lipid lowering: an important factor in preventing doxorubicin-induced heart failure. Am. J. Pathol., 150(2), 727–734 (1997).
   PubMed Web of Science ®Google Scholar
• Iliskovic N , HasinoffBB, MaliszaKL, LiT, DanelisenI, SingalPK. Mechanisms of beneficial effects of probucol in doxorubicin cardiomyopathy. Mol. Cell. Biochem., 196(1–2), 43–49 (1999).
   PubMed Web of Science ®Google Scholar
• Li T , DanelisenI, Bello-KleinA, SingalPK. Effects of probucol on changes of antioxidant enzymes in doxorubicin-induced cardiomyopathy in rats. Cardiovasc. Res., 46(3), 523–530 (2000).
   PubMed Web of Science ®Google Scholar
• Li T , SingalPK. Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation, 102(17), 2105–2110 (2000).
   PubMed Web of Science ®Google Scholar
• De Flora S , BennicelliC, SerraD, IzzottiA, CesaroneCF. Role of glutathione and N-acetylcysteine on the mutagenicity and carcinogenesis. In: Absorption and Utilization of Amino Acids (Volume 3). Friedman M (Ed.). CRC Press, FL, USA, 19–53 (1989).
   Google Scholar
• Myers CE , BonowR, PalmeriSet al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin. Oncol. , 10(1), 53–55 (1983).
   PubMed Web of Science ®Google Scholar
• Frishman WH . Carvedilol. Drug Therapy, 339(24), 1759–1765 (1998).
   Google Scholar
• Yue TL , ChengHY, LyskoPGet al. Carvedilol, a new vasodilator and beta adrenoreceptor antagonist, is an antioxidant and free radical scavenger. J. Pharmacol. Exper. Therap. , 263(1), 92–98 (1992).
   PubMed Web of Science ®Google Scholar
• Feuerstein GZ , RuffoloRR Jr. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur. Heart J., 16, 38–42 (1995).
   PubMed Web of Science ®Google Scholar
• Noguchi N , NishinoK, NikiE. Antioxidant action of the antihypertensive drug, carvedilol, against lipid peroxidation. Biochem. Pharmacol., 59(9), 1069–1076 (2000).
   PubMed Web of Science ®Google Scholar
• Matsui H , MorishimaI, NumaguchiY, TokiY, OkumuraK, HayakawaT. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci., 65(12), 1265–1274 (1999).
   PubMed Web of Science ®Google Scholar
• Fazio S , PalmieriEA, FerravanteB, BoneF, BiondiB, SaccaL. Doxorubicin-induced cardiomyopathy treated with carvedilol. Clin. Cardiol., 21(10), 777–779 (1998).
   PubMed Web of Science ®Google Scholar
• Spallarossa P , GaribaldiS, AltieriPet al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J. Mol. Cell. Cardiol. , 37(4), 837–846 (2004).
   PubMed Web of Science ®Google Scholar
• Nakamae H , TsumuraK, TeradaYet al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer , 104(11), 2492–2498 (2005).
   PubMed Web of Science ®Google Scholar
• Tokudome T , MizushigeK, NomaTet al. Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry. J. Cardiovasc. Pharmacol. , 36(3), 361–368 (2000).
   PubMed Web of Science ®Google Scholar
• Fischer PW , SalloumF, DasA, HyderH, KukrejaRC. Phosphodiesterase-5 inhibition with Sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation, 111(13), 1601–1610 (2005).
   PubMed Web of Science ®Google Scholar
• Hanley PJ , DröseS, BrandtUet al. 5-hydroxydecanoate is metabolised in mitochondria and creates a rate-limiting bottleneck for beta-oxidation of fatty acids. J. Physiol. , 562(2), 307–318 (2005).
   PubMed Web of Science ®Google Scholar
• Di X , GenningsC, BearHDet al. Influence of the phosphodiesterase-5 inhibitor, Sildenafil, on sensitivity to chemotherapy in breast tumor cells. Breast Cancer Res. Treat. , 124(2), 349–360 (2010).
   PubMed Web of Science ®Google Scholar
• Essayan DM . Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol., 108(5), 671–680 (2001).
   PubMed Web of Science ®Google Scholar
• Asmis R , WangY, XuL, KsgatiM, BegleyJG, MieyalJJ. A novel thiol oxidation-based mechanism for adriamycin-induced cell injury in human macrophages. FASEB J., 19(13), 1866–1868 (2005).
   PubMedGoogle Scholar
• Li W , LamMS, BirkelandAet al. Cell-based assays for profiling activity and safety properties of cancer drugs. J. Pharmacol. Toxicol. Methods. , 54(3), 313–319 (2006).
   PubMedGoogle Scholar
• Raja SG , DantonMD, MacArthur,KJ, PollockJC. Effects of escalating doses of sildenafil on hemodynamics and gas exchange in children with pulmonary hypertension and congenital cardiac defects. J. Cardiothorac. Vasc. Anesth., 21(2), 203–207 (2007).
   PubMed Web of Science ®Google Scholar
• Karatza AA , BushA, MageeAG. Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Int. J. Cardiol., 100(2), 267–273 (2005).
   PubMed Web of Science ®Google Scholar
• Baquero H , SolizA, NeiraF, VenegasME, SolaA. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics, 117(4), 1077–1083 (2006).
   PubMed Web of Science ®Google Scholar
• Juliana AE , AbbadFCB. Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil. Eur. J. Pediatr., 164(10), 626–629 (2005).
   PubMed Web of Science ®Google Scholar
• Diez JJ , IglesiasP. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur. J. Endocrinol., 148(3), 293–300 (2003).
   PubMed Web of Science ®Google Scholar
• Konishi M , HaraguchiG, OhigashiHet al. Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK upregulation. Cardiovasc. Res. , 89(2), 309–319 (2011).
   PubMed Web of Science ®Google Scholar
• Li L , TakemuraG, LiYet al. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation , 113(4), 535–543 (2006).
   PubMed Web of Science ®Google Scholar
• Hasinoff BB . The interaction of the cardioprotective agent ICRF-187 [+)-1, 2-bis(3, 5 dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of doxorubicin. Agents Actions, 26(3–4), 378–385 (1989).
   PubMedGoogle Scholar
• Speyer JL , GreenMD, Zeleniuch-JacquotteAet al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol. , 10(1), 117–127 (1992).
   PubMed Web of Science ®Google Scholar
• Swain SM , WhaleyFS, GerberMC, EwerMS, BianchineJR, GamsRA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J. Clin. Oncol., 15(4), 1333–1340 (1997).
   PubMed Web of Science ®Google Scholar
• Wexler LH , AndrichMP, VenzonDet al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J. Clin. Oncol. , 14(2), 362–372 (1996).
   PubMed Web of Science ®Google Scholar
• Swain SM , WhaleyFS, GerberMCet al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol. , 15(4), 1318–1332 (1997).
   PubMed Web of Science ®Google Scholar
• Lopez M , ViciPet al., Di Lauro L Randomized prospective clinical trial to evaluate cardioprotection of dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J. Clin. Oncol., 16(1), 86–92 (1998).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , ScullyRE, LipsitzSRet al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. , 11(10), 950–961 (2010).
   PubMed Web of Science ®Google Scholar
• Tebbi CK , LondonWB, FriedmanDet al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin‘s disease. J. Clin. Oncol. , 25, 493–500 (2007).
   PubMed Web of Science ®Google Scholar
• Herman EH , ZhangJ, RifaiNet al. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother. Pharmacol. , 48(4), 297–304 (2001).
   PubMed Web of Science ®Google Scholar
• Barry EV , VroomanLM, DahlbergSEet al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J. Clin. Oncol. , 26, 1106–1111 (2008).
   PubMed Web of Science ®Google Scholar
• Vrooman LM , NeuberDS, StevensonKEet al. The low incidence of secondary acutemyelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur. J. Cancer , 47(9), 1373–1379 (2011).
   PubMed Web of Science ®Google Scholar
• Schuchter LM , HensleyML, MeropolNJ, WinerEP. Update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol., 20(12), 2895–2903 (2002).
   PubMed Web of Science ®Google Scholar
• Yang JL , FernandesDJ, SpeicherL, CapizziRL. Biochemical determinants of the cytoprotective effect of amifostine. Proc. Am. Cancer Res., 36, 3725 (1995).
   Google Scholar
• Calabro-Jones PM , AguileraJA, WardJF, SmolukGD, FaheyRC. Uptake of WR-2721 derivatives by cells in cultures: identification of the transported form of the drug. Cancer Res., 48(13), 3634–3640 (1988).
   PubMed Web of Science ®Google Scholar
• Nazeyrollas P , FrancesC, PrevostAet al. Efficiency of amifostine as a protection against doxorubicin toxicity in rats during a 12-day treatment. Anticancer Res. , 23(1A), 405–409 (2003).
   PubMed Web of Science ®Google Scholar
• Dragojevic-Simic VM , DobricSL, BokonjicDRet al. Amifostine protection against doxorubicin cardiotoxicity in rats. Anticancer Drugs , 15(2), 169–178 (2004).
   PubMed Web of Science ®Google Scholar
• Herman EH , FerransVJ. Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1, 2-bis (3, 5-dioxopipreazine-1-yl) propane (ICRF-187). Cancer Res., 41(9 Pt 1), 3436–3440 (1981).
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med., 325(5), 293–302 (1991).
   PubMed Web of Science ®Google Scholar
• Haq MM , LeghaSS, ChoskiJet al. Doxorubicin-induced congestive heart failure in adults. Cancer , 56(6), 1361–1365 (1985).
   PubMed Web of Science ®Google Scholar
• Redfield MM , GershBJ, BaileyKR, RodehefferRJ. Natural history of incidentally discovered asymptomatic idiopathic dilated cardiomyopathy. Am. J. Cardiol., 74(7), 737–739 (1994).
   PubMed Web of Science ®Google Scholar
• Sieswerda E , van Dalen EC, Postma A, Cheuk DK, Caron HN, Kremer LC: Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Syst. Rev., 7(9), CD008011 (2011).
   Google Scholar
• Lipshultz SE , VlachSA, LipsitzSRet al. Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics , 115, 1613–1622 (2005).
   PubMed Web of Science ®Google Scholar
• Silber JH , CnaanA, ClarkBJet al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J. Clin. Oncol. , 22(5), 820–828 (2004).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , LipsitzSR, SallanSEet al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood Cancer J. Clin. Oncol. , 20, 4517–4522 (2002).
   PubMed Web of Science ®Google Scholar
• Mertens AC , SencerS, MyersCDet al. Complementary and alternative therapy use in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor study. Pediatr. Blood Cancer , 50, 90–97 (2008).
   PubMed Web of Science ®Google Scholar
• Ibsen S , ZahavyE, WrasdiloW, BernsM, ChanM, EsenerS. A novel doxorubicin prodrug with controllable photolysis activation for cancer chemotherapy. Pharm. Res., 27(9), 1848–1860 (2010).
   PubMed Web of Science ®Google Scholar
• Young K , HareJM. Stem cells in cardiopulmonary development: Implications for novel approaches to therapy for pediatric cardiopulmonary diseases. Progr. Pediatr. Cardiol., 25(3), 37–49 (2008).
   Google Scholar
• Assmus B , SchachingerV, TeupeCet al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation , 106(24), 3009–3017 (2002).
   PubMed Web of Science ®Google Scholar
• Schachinger V , AssmusB, BrittenMBet al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI trial. J. Am. Coll. Cardiol. , 44(8), 1690–1699 (2004).
   PubMed Web of Science ®Google Scholar
• Wollert KC , MeyerGP, LotzJet al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomized controlled clinical trial. Lancet , 364, 10–16 (2004).
   PubMed Web of Science ®Google Scholar
• Meyer GP , WollertKC, LotzJet al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months‘ follow-up data from the randomized, controlled BOOST (BOnemarrOw transfer to enhance ST-elevation infarct regeneration)trial. Circulation , 113(10), 1287–1294 (2006).
   PubMed Web of Science ®Google Scholar
• Pillekamp F , ReppelM, BrockmeierK, HeschelerJ. Stem cells and their potential relevance to paediatric cardiology. Cardiol. Young, 16(2), 117–124 (2006).
   PubMed Web of Science ®Google Scholar

Website

• Childrens Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers (2008). www.survivorshipguidelines.org
   Google Scholar